Related Experiment Video
Updated: Apr 22, 2026
08:15
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.1K
Antidiabetic effect of the α-lipoic acid γ-cyclodextrin complex
Yuki Naito1, Naoko Ikuta2, Daisuke Nakata3
1Department of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Chemistry, Kyoto Pharmaceutical University, 5, Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto 607-8414, Japan.
Journal of Clinical Biochemistry and Nutrition
|October 17, 2014
Summary
A novel alpha-lipoic acid gamma-cyclodextrin complex effectively lowers HbA1c in type 2 diabetes models. This compound activates AMP-activated protein kinase, suggesting a new therapeutic approach for managing blood sugar levels.
Area of Science:
- Metabolic diseases
- Pharmacology
- Biochemistry
Background:
- Type 2 diabetes mellitus (T2DM) is a growing global health concern with serious complications.
- Alpha-lipoic acid (ALA) has a known relationship with diabetes management.
- Existing treatments for T2DM include pharmaceuticals and specific health foods.
Purpose of the Study:
- To evaluate the efficacy of an alpha-lipoic acid gamma-cyclodextrin complex in managing T2DM.
- To investigate the mechanism of action, specifically the activation of AMP-activated protein kinase (AMPK).
Main Methods:
- Utilized KKA(y) mice, an animal model for T2DM.
- Administered ALA and ALA-γ-cyclodextrin complex to the mice.
- Assessed HbA1c levels and AMPK phosphorylation in liver tissue.
Main Results:
- The ALA-γ-cyclodextrin complex demonstrated a significant HbA1c lowering effect in T2DM animal models.
- The complex strongly induced the phosphorylation of AMPK, a key regulator of cellular energy homeostasis.
- These effects suggest a potential mechanism for suppressing postprandial hyperglycemia.
Conclusions:
- The ALA-γ-cyclodextrin complex exhibits a notable antidiabetic effect.
- This complex may serve as a promising therapeutic agent for T2DM by enhancing AMPK activation and controlling blood glucose levels.
- The findings support the potential of this complex as an adjunct therapy, similar to the effects of exercise.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
937
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
937
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
982
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
982
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
997
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
997
01:16Hormones Regulating Blood Glucose
7.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.2K